Related Experiment Video

Updated: Mar 20, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.7K

Costed Treatment Pathways of Diffuse Large B Cell Lymphoma in a UK Population-Based Cohort: A Patient Level

H I Wang1, A Smith1, E Roman1

  • 1University of York, York, UK.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|May 21, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K

Related Experiment Videos

Last Updated: Mar 20, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.7K
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K

Articles linked to this work by shared authors, journal, and citation graph.

Characteristic findings of cervical Papanicolaou tests from transgender patients on androgen therapy: Challenges in detecting dysplasia.

Cytopathology : official journal of the British Society for Clinical Cytology·2018

Outbreak of gentamicin-resistant, meticillin-susceptible Staphlococcus aureus on a neonatal unit.

The Journal of hospital infection·2017

Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network.

British journal of cancer·2015

The peterborough hospital human tissue bank.

Alternatives to laboratory animals : ATLA·2014

An Application of Iterative Health Economic Evaluation: An Update on the Early Cost Effectiveness of Whole-Genome Sequencing in Advanced Non-small-Cell Lung Cancer.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Does conventional cost-effectiveness analysis disadvantage treatments for severe disease? Evidence from U.S. value assessments.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Incorporating Equity Considerations Related to Financial Protection Through Extended Cost-Effectiveness Analysis: A Systematic Review.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

How Long Should We Wait? The Impact of Immature Data on Colorectal Cancer Decision Modeling.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

What Age is Appropriate for Self-Reporting EQ-5D-Y-3L? Chinese Insights from a Sample of Children Aged 6-11 years.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

How National Volume-Based Procurement Reshapes Drug Prices and Public Spending in China.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

The mechanism of malignant progression in extramammary Paget's disease (EMPD): hallmarks of EMPD.

Medical molecular morphology·2026

Late Endocrine and Organ Toxicities After Treosulfan-Based Conditioning in Pediatric Hematopoietic Cell Transplantation: A Systematic Review.

Pediatric blood & cancer·2026

ENCERT: A Multisite Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide, and Etoposide in Relapsed T-Cell Lymphoblastic Leukemia/Lymphoma.

Pediatric blood & cancer·2026

Cathepsin D as a central regulator of extracellular matrix remodeling in wound healing and chronic tissue pathologies.

Tissue barriers·2026

Outcomes of CHOP versus CHOEP/EPOCH in aggressive adult T-cell leukemia/lymphoma: an international cohort analysis.

Haematologica·2026

"Bendamustine monotherapy induces high response rates and STAT3 inhibition in high burden T-cell large granular lymphocytic leukemia".

Haematologica·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us